



Press Release

March 26, 2015

Corline appoints former Nycomed EVP as new board member

Swedish company Corline Biomedical AB, maker and distributor of a proprietary and unique heparin coating technology for use in regenerative medicine, has appointed Kerstin Valinder-Strinnholm as non-executive member of the board of directors.

“Mrs Valinder-Strinnholm brings with her a wealth of experience of product and business development from the pharmaceutical industry which is a perfect match for Corline as we increase our focus on developing ground-breaking drug products for transplantation and cell therapies”, comments CEO Henrik Nittmar.

Kerstin Valinder-Strinnholm has more than 30 years’ experience in the pharma industry, initially focussing on sales and marketing, more recently in strategic and business development. After some 15 years in AstraZeneca, responsible for Business Strategy & Licensing for the Gastro Intestinal Division, Valinder-Strinnholm switched to Nycomed in 1999 as EVP of Corporate Development. Nycomed’s growth strategy relied on acquisitions and in-licensing of complementary technologies and products, hence Kerstin was instrumental to value building of the company. In 2011, Nycomed was acquired by Takeda for \$14bn. Kerstin is now heading her own consultancy business, focussing on pharmaceutical companies.

“I am excited to join the team around Corline and to support its strategy to develop new therapeutics in the evolving field of regenerative medicine. Big Pharma has been looking for input into their development pipelines for quite some years and many people believe that it will be found in small biotech firms like the one Corline represents. I see my role in the board as one of bringing a pharma perspective to Corline’s very interesting development pipeline. As the company is rapidly approaching clinical trials, the timing is perfect”, concludes Kerstin Valinder-Strinnholm.

About Corline

Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes proprietary heparin based substances for better handling of immune response associated with clinical use of medical devices and regenerative medicine (cell therapy and transplantation). In 2011, the market for regenerative medicine totalled a 3.5 bn USD turnover, employing over 14,000 individuals and with an 80 % share being focused in the US. The US based market analysis company Life Science Intelligence, estimates the total potential to be over 100 bn USD.

Corline's heparin substances can be used to coat living cells and tissue without compromising their biological functions. The products *Cytoparin™* for cell therapy and *Renaparin™* for kidney transplantation help attenuate the local inflammation that is formed on and around grafts at transplantation and promotes new blood vessels to grow more quickly to support the graft. For patients, Corline's products may lead to improved clinical outcome and a more rapid recovery from treatment.

Corline is a public company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.

For more information, please contact:

Henrik Nittmar, CEO
Tel. +46 (0)18 71 30 90
henrik.nittmar@corline.se
www.corline.com

Corline Systems AB
Box 956
715 09 Uppsala
SWEDEN